Tumor lysis syndrome induced by tebentafusp.
adverse events
immunotherapy
tebentafusp
tumor lysis syndrome
uveal melanoma
Journal
Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
medline:
23
10
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
Tebentafusp, a bispecific T-cell receptor fusion protein directed against gp100 and CD3, can improve survival in patients with metastatic uveal melanoma and was recently approved for the treatment of Tebentafusp is a new treatment for a type of eye cancer called uveal melanoma. It helps the body's defense system fight against cancer cells and has shown promise in helping patients live longer. However, not all patients with uveal melanoma can use this treatment. Only those who have a specific gene marker called
Autres résumés
Type: plain-language-summary
(eng)
Tebentafusp is a new treatment for a type of eye cancer called uveal melanoma. It helps the body's defense system fight against cancer cells and has shown promise in helping patients live longer. However, not all patients with uveal melanoma can use this treatment. Only those who have a specific gene marker called
Identifiants
pubmed: 37661909
doi: 10.2217/imt-2023-0093
doi:
Substances chimiques
tebentafusp
N658GY6L3E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM